Larry Ereshefsky

Dr. Ereshefsky is the Chief Scientific Officer at CNS. Dr. Ereshefsky is an internationally recognized thought leader in clinical translational CNS research with a proven track record in designing and performing Phase I/IIa and clinical pharmacology studies. He pioneered neurocircuitry/biomarker-based (RDoC) studies incorporating qEEG, ERP, PSG, fMRI, MRS, PET, pain models, and CSF collection. He has more than 45 years of drug discovery and development experience including Program Director Psychopharmacology/ Professor, University of Texas Health San Antonio, CSO for California Clinical Trials, and Global CNS Lead, Early Phase PAREXEL. During his career, he served as a PI on more than 100 studies and several hundred more as a sub-I. Dr. Ereshefsky has been a designer and investigator on over 100 Asian Bridging trials, and he co-created the ex-Japan, US-based strategy.

Over the last four decades, Dr. Ereshefsky has contributed 100+ Scholarly Presentations/Keynote addresses and published 200+ Research/ Clinical practice Articles/ Abstracts/ Posters, of which 150 are Peer Reviewed. Since the early 1970s, he has served on numerous professional societies as an officer or board member. He served two terms on the FDA Psychopharmacological Drugs Advisory Committee, several terms on the USP-Panel for Psychiatry, and Co-chairs two ISCTM Working Groups on Behavioral and Psychological Symptoms of Dementia, with FDA, EMA, AAIC, NIMH, and IPA participation, resulting in Diagnostic Criteria and publications delineating a road map for drug development.

Dr. Ereshefsky received his Pharm.D. from the University of Southern California. His post Post- Graduate Residency in Psychiatric Pharmacy/ Psychopharmacology was completed at LA County Medical Center.